Archive for December, 2020

$WTER Is Set for Market Expansion Through Key Partnerships

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, is set to expand into hospitality and foodservice sectors. As part of this effort, the company has entered into agreements with two strategic partners: Dot Foods Inc., the largest food redistribution company in the U.S., and the Independent Broker Alliance (“IBA”), a renowned professional alliance of 30 independent foodservice sales agencies. With these two agreements in place, WTER targets the entire hospitality and foodservice ecosystem, a very large addressable market. “Adding the largest foodservice redistributor, Dot Foods, to our growing list of channel partners is another milestone for the company,” said WTER president and CEO Richard Wright in a recent update. “Every year, Dot Foods sells millions of cases of beverages to its customers. This relationship will give us an entry into the hospitality industry, which we view as a significant opportunity for our growing lifestyle brands. There are over 600,000 restaurants and foodservice establishments that will now have access to our full line of products.”

To view the full article, visit: https://cnw.fm/ZMcam

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on $WTER Is Set for Market Expansion Through Key Partnerships

$SGTM Profitably Transforms Hurricane Waste into Environmentally-Beneficial Organic Products

December 31, 2020
  • Active hurricane season projected for 2021 according to recent report examining factors contributing to Atlantic basin hurricane activity
  • Hurricanes cause extreme damage due to strong winds, flooding and storm surges that create large amounts of natural waste
  • SGTM provides synergistic solutions to waste disposal problems created by hurricanes that benefit the environment

Not only did the 2020 hurricane season in the United States start early, but it broke records with so many storms that the National Hurricane Center used every name in its pre-determined list (https://ibn.fm/oaVg2). Meteorologists are now predicting that 2021 may be another active season that will likely result in serious repercussions on urban infrastructure and the environment (https://ibn.fm/TynAU). Sustainable Green Team (OTC: SGTM), a leading provider of environmentally-beneficial solutions for tree and storm waste disposal, will be on call to provide remediation efforts that divert natural storm waste from landfills and transform it into organic mulch products and playground surfacing material that benefit the environment.

Following a record 2020 hurricane season, 2021 is projected to be another active year, according to recently published research examining factors contributing to Atlantic basin hurricane activity. “Early indications are that 2021 could potentially be another active season,” said Phil Klotzbach a meteorologist from Colorado State University and specialist in Atlantic basin seasonal hurricane forecasts. “Right now, we have about a 50% chance of having an above-normal hurricane season.”

Hurricanes can cause extreme damage that results in physical, economic and environmental hardship. Strong winds can wield power so immense that they uproot trees and turn them into dangerous projectiles flying through the air. Accordingly, flooding can cause extreme damage to the foundations of buildings while destroying vehicles and vegetation. These two threats, however, pose moderate risks when compared to storm surges that cause the sea level to rapidly rise and then fall, decimating everything in their path as the hurricane makes its way onto land.

The consequences of these storms on people, infrastructure and the environment can be devasting, and the 2020 season was no exception. From its early start on May 14, 2020, the record-breaking season had so many storms that, for the second time in its history, the National Hurricane Center used every name in the pre-determined list and used the Greek alphabet for the remainder of the season.

SGTM played a significant role in the remediation efforts for many of these hurricanes, such as Hurricane Laura – an exceptionally violent storm that ravaged Louisiana and caused billions of dollars in damage (https://ibn.fm/DH632). Rather than allow the abundant tree and vegetative waste to add to the burden imposed on municipal landfills, SGTM acted quickly through its strategic partners to collect the waste and transport it to designated processing facilities for transformation into environmentally-beneficial products.

SGTM has grown and expanded throughout 2020 with numerous new contracts, strategic partnerships and operational investments that will enable the company to tackle whatever 2021 will bring its way. With a mission of protecting and serving the environment, SGTM is positioned to continue growing by offering services that transform serious problems into profits for the benefit of its clients and the communities the company serves.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/6Kj3E.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on $SGTM Profitably Transforms Hurricane Waste into Environmentally-Beneficial Organic Products

$SRAX Announces Extension of Right to Receive BIGtoken Special Dividend

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire, has extended the expiration time for its previously announced special dividend right. The extension is from Dec. 31, 2020, to on or before 5 p.m., ET, on Dec. 31, 2021. SRAX issued the nontransferable right to receive at no charge a special dividend in September 2020. The right was issued to holders of the company’s Class A common stock as well as certain holders of the company’s common stock equivalents. The special dividend, if and when declared, will comprise such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by SRAX management. The dividend right was originally set to expire on or before 5 p.m., ET, on Dec. 31, 2020. Today’s announcement extends that deadline to Dec. 31, 2021. Other information released by the company regarding the special dividend notes that it will be an analog security rather than digital, that it will not be a cryptocurrency, and that it is expected to be a fractional non-voting security, if and when issued.

To view the full press release, visit http://ibn.fm/VIo1V

About SRAX

SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform Sequire,  companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, please visit www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on $SRAX Announces Extension of Right to Receive BIGtoken Special Dividend

$NETE Mullen Merger Future Looks Bright with Projected Lower kWh Battery Prices

  • Experts predict average price per kilowatt-hour for batteries will hit $101 by 2021, resulting in lower EV prices
  • Battery prices would make an EV “cheaper than a gas car to buy,” observes “Car and Driver” article
  • Mullen making strong strides toward production of several EV models

With the news from Bloomberg that the average price per kilowatt-hour for batteries is projected to hit $101 by 2021, it seems plausible that electric vehicles (“EVs”) may be comparable in price to gasoline-powered autos (https://ibn.fm/qofPF). That news paints a bright future for Net Element (NASDAQ: NETE), a global financial technology and value-added solutions group that has entered into a binding letter of intent to merge with privately held Mullen Technologies Inc., a Southern California-based electric vehicle company (https://ibn.fm/Fqg66).

“In the showroom, electric vehicles still cost more than their gasoline counterparts,” a recent “Car and Driver” article noted. “Sure there are tax credits, the maintenance is far cheaper, and charging can be cheaper than refueling in some cases. But it’s that sticker price that keeps some shoppers away from the electric powertrain. . . .

“Fortunately, it looks like the cost per kilowatt-hour is continuing to trend down, and according to a new report from energy research firm BloombergNEF (New Energy Finance), the market average should be $101 per kWh by 2023,” the article continued. “The $100-per-kWh price point is where experts expect the cost of EVs to match the prices of comparable gas-powered vehicles. If federal and state tax credits are still available at that time, it’s likely that they could make an EV cheaper than a gas car to buy.”

As NETE moves closer to closing the merger with Mullen, the progress Mullen is making toward production of EVs bodes well for the company. In October, Mullen began turning its high-voltage battery R&D center in Monrovia, California, into a state-of-the-art pilot manufacturing facility for its line of fully electric SUVs (https://ibn.fm/nztgs). With construction scheduled to be completed by April 2021, the company anticipated its first MX-05 SUVs will roll off the production line by Q2 2022.

With that in mind, Mullen begin taking pre-orders for its MX-05 SUV in October. The company is also taking pre-order for its Dragonfly K50, a pure electric, high-performance, limited-production sports car. In addition, the company has announced plans for its Mx-07 and MX-03 car models.

Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Earlier this year Net Element entered into a binding letter of intent to merge with Mullen Technologies in a stock-for-stock reverse merger. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on $NETE Mullen Merger Future Looks Bright with Projected Lower kWh Battery Prices

$UUUU Supply Agreement with Chemours Represents Commitment to Re-Establish US Rare Earth Supply Chain

  • UUUU has signed three-year supply agreement with Chemours Company to obtain minimum 2,500 tons of rare earth and uranium-bearing natural monazite ore per year
  • CEO notes company’s excitement about working with Chemours to help “reestablish U.S. rare earth production”
  • Responsible production of REES, uranium from natural monazite ore is important complement to company’s existing programs

In what could be called a milestone moment in re-establishing a fully integrated REE supply chain in the United States, Energy Fuels (NYSE American: UUUU) (TSX: EFR) has announced a three-year supply agreement with the Chemours Company (NYSE: CC) (https://ibn.fm/XO0tG). The agreement calls for Energy Fuels to receive a minimum of 2,500 tons of natural monazite ore per year, one of the highest-grade rare earth element (“REE”) minerals in the world. Energy Fuels will process this monazite at its 100%-owned White Mesa Mill in Southeast Utah to produce a marketable mixed REE carbonate.

“We are extremely excited about working with Chemours to help reestablish U.S. rare earth production,” said Energy Fuels president and CEO Mark S. Chalmers. “Chemours is a leader in the U.S. heavy mineral sands industry, and, together we are now taking an important first step in returning the REE supply chain back to the United States. We look forward to working with Chemours in the future to expand our mutual contributions to this important initiative.

“This is a proud moment for Energy Fuels, as we deploy our unique capabilities to benefit both the environment and our shareholders,” he continued. “Energy Fuels already produces uranium, which is the fuel for clean, carbon-free nuclear energy. And we periodically produce vanadium, which is used in the production of steel, aerospace alloys, and advanced grid-scale batteries used to store renewable energy. The responsible production of rare earths and uranium from natural monazite sand ores is an important clean-technology addition to those programs.”

Energy Fuels has long been an advocate for efforts made by the U.S. government to address the country’s overreliance on critical minerals needed for clean energy and advanced technologies from foreign sources and re-establish the rare earth and uranium supply chains with U.S. companies.

“Energy Fuels stands ready to do our part in bringing uranium, vanadium and rare earth element processing and production back to the United States. We have led uranium industry efforts in Washington DC over the past three years to bring the issue of mineral supply chain security to the forefront, beginning with our Uranium Section 232 Petition, in which we asked the President to impose quotas on uranium imports,” said Chalmers earlier this year (https://ibn.fm/0II41). “Energy Fuels strongly supports the President’s declaration of a national emergency and invoking the Defense Production Act to free up the immediate government funding required to bring uranium production back to the United States and reduce our current dependency on imports from foreign adversaries, while also helping to fund U.S. vanadium and rare earth element production.”

This supply agreement is tangible evidence of the the company’s active efforts to do all it can to bring production of these essential minerals back to the United States. This agreement should provide Energy Fuels with the natural monazite ore it needs to provide almost 10% of total current U.S. REE demand.

In addition, UUUU is seeking additional natural monazite ore from other suppliers in order to increase its production. The company has the capacity to produce approximately 50% of U.S. REE demand in a mixed REE carbonate. Energy Fuels is also working with the U.S. Department of Energy to determine the possibility of processing other types of REE and uranium-bearing ores at the White Mesa Mill.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities; the company also produces vanadium from certain of its projects, as market conditions warrant. Headquartered in Colorado, the company holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the country today, has a licensed capacity of over 8 million pounds of U3Oper year. The mill has the ability to produce vanadium when market conditions warrant and it was the largest U.S. supplier of high purity vanadium pentoxide in 2019. Energy Fuels is also completing final test-work for the production of REE carbonate from natural monazite ore, and expects to be in commercial rare earth production in 2021. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3Oper year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3Oper year.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on $UUUU Supply Agreement with Chemours Represents Commitment to Re-Establish US Rare Earth Supply Chain

Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy

  • Oregon is first state to permit supervised use of psilocybin, signaling shift in stigma
  • CYBN entering phase 2 of clinical study of sublingual psilocybin for the potential treatment of MDD
  • Newly discoverable data from psychedelic studies may potentially create entirely new marketplace of safe and effective drugs

Cybin (NEO: CYBN), a mushroom life sciences company, is working to become the first to bring a psilocybin drug to market targeting major depressive disorder (“MDD”). According to the National Institute of Mental Health, more than 18 million people in the United States — and 300 million people worldwide — experience major depression. Psilocybin has become a focus for academic institutions and companies whose clinical studies have been showing the effectiveness of psychedelics in mental health treatment. The stigmas around mushrooms are beginning to fade.

Most cities have decriminalized psilocybin, but Oregon is the first to permit supervised use statewide (https://ibn.fm/e3Spg). The passing of Measure 109 does not legalize the everyday use of psychedelic mushrooms but instead enables the regulated use of the shrooms in a therapeutic setting. Over the next two years, regulatory details will be worked out, including the qualifications required for therapists to use the mushrooms. The Oregon Health Authority will provide oversight for the program, and therapy recipients will undergo pre-screening, a supervised therapy session and post-use evaluation. Psilocybin is still considered a Schedule 1 drug.

Since 2018, the FDA has labeled psychedelic psilocybin a “breakthrough therapy” to treat MDD (https://ibn.fm/QCoge). This designation fast tracks the substance for clinical studies and for promising therapies that treat serious or life-threatening conditions and provide therapeutic benefits over available treatments (https://ibn.fm/REbvg).

On Nov. 4, 2020, John Hopkins Medicine researchers published their latest psilocybin study in “JAMA Psychiatry.” According to Alan Davis, PhD and adjunct assistant professor of psychiatry and behavioral sciences at John Hopkins University School of Medicine, the results could be a game-changer (https://ibn.fm/EY74h).

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” said Davis. “Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials.”

Cybind is at the forefront of companies conducting clinical trials and is entering phase 2 of its clinical study of sublingual psilocybin for the potential treatment of MDD at the beginning of 2021. The study’s objectives are to determine the appropriate dosing, evaluate clinical efficacy, and assess the safety and tolerability of psilocybin.

The company seeks to partner with esteemed individuals and institutions leading the way in the research and development of pharmaceutical uses of psilocybin. This desire led to a partnership with the Toronto Centre for Psychedelic Science (“TCPS”) where some of the first academic research on micro dosing was published (https://ibn.fm/PI0t1). Both Cybin and TCPS have high standards for scientific rigor and transparency. CYBN believes that newly discoverable data from psychedelic studies can potentially create an entirely new marketplace of safe and effective drugs.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on Cybin Inc. (NEO: CYBN) Targets Major Depressive Disorder with Breakthrough Therapy

$CNPOF Sells Interest in Italy-Based Canapar

Canopy Rivers (TSX: RIV) (OTC: CNPOF), through its wholly owned subsidiary, Canopy Rivers Corporation, on Wednesday announced its entry into a definitive share purchase agreement. Under the agreement, effective as of Dec. 30, 2020, with RAMM Pharma Corp. (CSE: RAMM), Canopy Rivers has sold its 49% common equity interest in Canapar Corp. to RAMM for consideration of up to $9.0 million. On closing, RAMM delivered a cash payment of $7.0 million to Canopy Rivers to purchase its 29,833,333 common shares in Canapar. The transaction also includes contingent consideration of $2.0 million, to be paid upon achievement of certain operational milestones and satisfied, at RAMM’s sole discretion, in either cash or through the issuance of common shares in RAMM to Canopy Rivers. “The divestment of our equity interest in Canapar represents an important reallocation of capital as we adjust our go-forward investment strategy,” said Narbé Alexandrian, president and CEO of Canopy Rivers. “We thank Canapar for their work and partnership. As Canopy Rivers turns a new page, however, it’s important to narrow our focus and recalibrate our capital deployment and exposure to better align with our new strategic direction.”

To view the full press releases, visit https://ibn.fm/hkeZX and https://ibn.fm/IUdMl

About Canopy Rivers Inc.

Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 17 companies across various segments of the cannabis value chain. The company believes that bringing together people, capital and ideas raises the potential of the entire cannabis industry. By leveraging industry insights, in-house expertise and thesis-driven approach to investing, Canopy Rivers aims to provide shareholders exposure to specialized and disruptive cannabis companies. Canopy Rivers’ mission is to invest in innovators across the cannabis value chain, help them grow, and ultimately create value by guiding these companies towards a monetization event. Together with its portfolio, the company is helping build the cannabis industry of tomorrow, today. For more information, visit www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, December 31st, 2020 Uncategorized Comments Off on $CNPOF Sells Interest in Italy-Based Canapar

$VTGN Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. The article covers the proposed mechanism of action of VistaGen’s investigational neuroactive nasal sprays, PH94B and PH10, currently in development as potential rapid-onset treatments for anxiety and depression disorders.* The publication details the proposed neural circuits mediating the mechanism of action of pherines, including PH94B and PH10, which are synthetic neuroactive steroids designed to engage nasal chemosensory receptors and produce rapid-onset anxiolytic and antidepressant effects. “PH94B and PH10 were discovered and developed for their specific therapeutic potential to treat anxiety and depression disorders, representing a new class of neuropharmaceuticals,” said Dr. Monti. “When current anxiolytics and antidepressants drugs are administered systemically, milligram-level doses of the drugs are often needed to achieve the desired therapeutic effects. In contrast, with the innovative pharmacology of PH94B and PH10, we believe only microgram-level doses administered intranasally onto the receptors in the nasal passage are required to achieve the desired neural activity.”

To view the full press release, visit: https://ibn.fm/wE9Qw

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn and Facebook.

*Monti, L., & Liebowitz, M. (2020). Neural circuits of anxiolytic and antidepressant pherine molecules. CNS Spectrums, 1-7. doi:10.1017/S109285292000190X

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $VTGN Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders

$SRAX Sequire Well Suited to Meet Radical Shift in Investor Relations Dynamics

December 30, 2020

SRAX Inc.’s (NASDAQ: SRAX) Sequire Well Suited to Meet Radical Shift in Investor Relations Dynamics

  • Investor relations teams have witnessed radical change in ongoing responsibilities over past few years
  • No longer limited to servicing existing and potential investors, IR teams must now respond to ESG queries, engage with both debt investors and credit rating agencies
  • Increased responsibilities have led to heightened need for supplemental tools to assist with influx of new data, to complement ongoing IR efforts
  • Sequire’s investor intelligence platform has partnered with publicly listed corporations to help provide further insight, assistance during investor engagement efforts

Investor relations (“IR”) teams have opted to refocus their strategy in what has been an unusual year for corporations across the world, seeking to emphasize both strategic engagement with existing shareholders as well as attraction of new potential investors. IR executives have also been drawn to advising corporations on their adherence towards emerging Environmental, Social and Governance (“ESG”) standards, while simultaneously maintaining and improving engagement with debt investors and ratings agencies alike. The consequent and extraordinary increase in role responsibilities and data requirements has worked in the favor of SRAX (NASDAQ: SRAX), a financial technology company focused on unlocking data and insights for publicly traded companies through Sequire, its proprietary investor intelligence platform. The platform has enjoyed a remarkable increase in demand for its services as of late, as IR teams seek to increase investor engagement during ongoing unprecedented global business conditions.

A recent investor relations-focused survey carried out by the Bank of New York Mellon (https://ibn.fm/SxbnT) found that engagement with existing and prospective institutional investors continued to be a top priority for corporate management and IR teams alike, with the latter group devoting 38 percent of their time to existing shareholders while spending a further 25.5 percent catering to prospective investors. However, in a sign of the shifting priorities of the investment community, over 71.3 percent of IR respondents declared that communicating with investors on ESG and Corporate Social Responsibility (“CSR”) issues was now an extension to their ongoing responsibilities.

Corporate IR teams have increasingly shifted towards adopting digital solutions and the data garnered from such mediums as a way of managing the increased demands on their time while simultaneously improving engagement with investors and stakeholders. The sharp uptick in demand for investor data and digital technologies had been mirrored by engagement levels witnessed on SRAX’s Sequire platform. Launched as a stand-alone platform in early 2020, Sequire today boasts over 1 million investors and traders on its platform as well as 91 publicly-listed corporate subscribers (https://ibn.fm/9Aqey) – a surge of growth largely driven by Sequire’s extensive range of services.

Sequire’s investor intelligence platform allows its subscribers to track their shareholders’ selling and buying trends, search and monitor key investors, track outstanding warrants, receive the latest company-specific news and media, and even create and send out customized shareholder surveys designed to elicit their stake-holders’ insights and opinions (https://ibn.fm/Pv2ma).

Perhaps most critically, Sequire allows IR teams to compensate for activities which have been supplanted due to the increased demands on their time. The BNY Mellon survey showed that in 2017, IR teams would spend 26.4 percent of their time catering to prospective institutional investors – a figure which would be reduced to only 25.5 percent by 2019.

Sequire’s management illustrated the platform’s potential to make up for what would traditionally have been a key task for investor relation teams. In one example, a single corporate subscriber using Sequire witnessed its number of individual shareholders skyrocket from 3,000 to over 360,000 during its tenure on the platform.

The investor relations function at publicly listed corporations has undergone a dramatic transformation as of late – with increased regulatory burdens and social distancing leading to a heightened need for both investor intelligence platforms as well as digital distribution channels to facilitate investor communications. Sequire has sought to transform its platform to cater to the growing needs of the IR community, placing it in good stead to benefit from the ongoing evolution of investor relations.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $SRAX Sequire Well Suited to Meet Radical Shift in Investor Relations Dynamics

$POAI Cancels Upcoming Special Meeting of Stockholders

Predictive Oncology’s (NASDAQ: POAI) Board of Directors has announced that it will cancel the Special Meeting of Stockholders that was scheduled for today. Originally scheduled for Dec. 1, 2020, the meeting was adjourned on that date and rescheduled for Dec. 30 because a quorum had not been reached. As of the rescheduled date, the required quorum had still not been reached, with only 47% of the outstanding shares having been voted. In cancelling the meeting, the Board of Directors for POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, noted that it was not practical to incur the cost of continuing to adjourn the meeting to solicit proxies, because approval of the reincorporation proposal would require not just a majority of the shares voted but the affirmative vote of a majority of the company’s outstanding shares. The board observed that nearly 88% of the shares that had been voted at the special meeting were in support of the proposed reincorporation of the company from Delaware to Nevada; the reason for that proposal is, in part, because of Delaware’s steep franchise taxes. The board will continue to pursue stockholder approval for reincorporation.

To view the full press release, visit http://ibn.fm/kyNgN

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $POAI Cancels Upcoming Special Meeting of Stockholders

$NETE Announces Mullen Technologies Receives LOI for Purchase of 1,500 MX-05 EVs

Net Element (NASDAQ: NETE) is a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately held Mullen Technologies Inc. Mullen recently executed a nonbinding Letter of Intent (“LOI”) with Unlimited Electrical Contractors Corp (“UEC”), a premiere electrical contractor based in Pompano Beach, Florida. The LOI outlines agreements for the purchase of up to 10,000 of Mullen’s MX-05 electric vehicles (“EVs”), with an initial purchase order of 1,500 MX-05s, valued at an estimated $75 million. The LOI states that UEC may order an additional 8,500 vehicles by 2025. UEC is working toward being the first electrical contractor with an all-electric service fleet. The agreement is for a modified variant of the MX-05, an electric crossover SUV based on a skateboard EV platform and a unibody frame available in either a single or dual electric motor configuration. “We’re very excited to work with UEC and are very fortunate that they see the value in Mullen and the MX-05 for their business,” said Mullen Technologies CEO and Chairman David Michery in the press release. “UEC’s order is the first of many commercial fleet relationships we are currently working on. The skateboard platform and low center of gravity of the MX-05 allows us to easily configure the vehicle for many different types of commercial trade use.”

To view the full press release, visit http://ibn.fm/JcWex

About Net Element Inc.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). The contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visit www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $NETE Announces Mullen Technologies Receives LOI for Purchase of 1,500 MX-05 EVs

$UUUU ABB Deploys Automation, Electrification Technologies to Increase Sustainable Underground Mining

ABB is a technology firm focused on achieving a productive and sustainable future. Its automation solutions and electrification knowledge have been utilized in a futuristic project that aims to increase productivity by 50% while generating no carbon dioxide emissions.

The global tech company has provided connected operations and control-management systems as well as mobile-operator workplaces with high visualization as part and parcel of a worldwide mining partnership to reduce the climate impact.

The project, referred to as the Sustainable Underground Mining, was designed by LKAB. The aim of the project is to set a new sustainable mining world standard in collaboration with Epiroc, ABB, Combitech and Sandvik. LKAB’s key business is the mining and processing of iron ore and for the steel industry.

The framework outlines the project’s objectives for deeper mining, zero carbon dioxide emissions, productivity growth and safe mines for individuals.

In addition to its partnership with LKAB, ABB will continue its knowledge contributions with regard to automation and workplaces. The partnership’s goal is to discover smarter solutions and alternative methods for mining in the future. A virtual test mine and test work in Northern Sweden’s Kiruna mine will be used to study the best way to establish an autonomous production system that is carbon dioxide free.

The Konsuln orebody is used to show workplaces in the future in an environment that is decentralized and that uses autonomous electric mobile transport systems efficiently. Additionally, the organizations involved will be provided with real-time process information.

ABB is comprised of a big team willing to commit a significant amount of time to the project. The firm includes experts in research and digitalization as well as in automation and electrification. The ABB automation and electrification solutions will have been installed fully by 2022. The goal is that a new mining production standard will be established worldwide by the year 2030.

New technology will be designed and tested in a real mining environment in the Sustainable Underground Mining project to ensure that the natural resource industry in Sweden can grow and generate employment opportunities while remaining competitive both nationally and locally. In the future, digitalized and autonomous machines and mine experts and professionals will work together.

For the project to be implemented, partners and a significant investment on a national scale will be needed. The partners are now seeking collaborations with universities, the Swedish state and research institutes as well as additional suppliers.

Meanwhile, mining firms are continuing their operations amid the pandemic in the most safe and effective ways possible. For instance, Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) has a globally outstanding portfolio of uranium production.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $UUUU ABB Deploys Automation, Electrification Technologies to Increase Sustainable Underground Mining

Cybin Inc. (NEO: CYBN) New Hampshire Supreme Court Supports Freedom for Psychedelic Use in Religious Ceremonies

Last week, the Supreme Court of New Hampshire overturned an earlier conviction of a resident from the North Country, whose charges of psilocybin mushroom possession were filed in 2018. The court ruled that the earlier conviction conflicted with the religion the defendant practices, which is Native American based.

The sitting justices stated in a unanimous ruling that as compared to protections in the U.S. constitution, the right of religion in the New Hampshire constitution was stronger. Under the U.S. constitution, sterner balancing tests are required in the event that the illegal drugs in question are used for religious practices.

The Coos County Superior Court’s decision stated that Jeremy D. Mack had practiced an earth-based religion for years and had become a member of a branch of the Oklevueha Native American Church known as the Oratory of Mystical Sacraments. After joining the church, the resident of Colebrook was provided with a membership card, which permitted him to consume psilocybin mushrooms sacramentally.

The church had limitations that applied to the ingestion of the sacrament, stating that the sacrament was not to be taken around children, when shooting firearms, in public or when driving. Instead, the church strongly recommended that the sacrament be consumed in seclusion.

Mack had been found guilty of possession of psilocybin in 2018 after state police found the hallucinogenic mushrooms during a search for weapons under a confiscation order that involved a different civil case.

Psilocybin has been classified as a Schedule 1 drug by the federal government. This means that the hallucinogenic drug is not allowed to be used in a medical setting and has a high potential for abuse. Other drugs that have been classified in this category include LSD, marijuana and heroin.

The four justices stated that the trial judge who presided over the trial that ultimately led to the conviction of Mack made a mistake in the legal rulings. Echoing an 1868 opinion, one of the justices, Supreme Court Justice James Bassett, stated that in Part I, Article 5, there existed a universal declaration and statement that cited that every individual has the unalienable and natural right to belong to the religion persuasion of his choice, to worship God publicly and privately in the season and manner that is most agreeable to the individual, dictated by reason and his own conscience.

He then added that the Constitution of New Hampshire protected both practices and beliefs while the U.S. constitution protected religious beliefs.

Still on the matter if psychedelic substances, a number of companies are focused on leveraging the emerging opportunities in this sector. For instance, Cybin Inc. (NEO: CYBN), a Canadian-based firm, has two divisions (Natures Journey Inc. and Serenity Life Sciences), each of which is focused on therapeutic nutraceutical and medicinal psychedelic products respectively.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on Cybin Inc. (NEO: CYBN) New Hampshire Supreme Court Supports Freedom for Psychedelic Use in Religious Ceremonies

$CRTD Announces $7.77M Private Placement

Creatd (NASDAQ: CRTD), the parent company of Vocal, today announced its entry into definitive securities purchase agreements in connection with a private placement of its Series E Convertible Preferred Stock (the “Preferred Stock”) and warrants to existing shareholders as well as new institutional investors. Upon the closing of the financing, expected to occur on or prior to Jan. 4, 2021, Creatd expects to receive approximately $7.77 million in gross proceeds, not including any proceeds that may be received upon exercise of the warrants. The company intends to use the net proceeds of the financing to satisfy Nasdaq’s stockholders’ equity listing requirements as well as to further accelerate its business plan, social media and digital marketing initiatives, pay non-commission financing expenses, repay all of its minimal remaining outstanding debt, and fund any additional working capital needs and accretive acquisitions.

To view the full press release, visit https://ibn.fm/xcYfw

About Creatd Inc.

Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology, Vocal, is a best-in-class creator platform. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.

NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $CRTD Announces $7.77M Private Placement

$CNPOF RAMM Pharma Enters European Cannabis Market with Strategic Investment in Canapar Corp.

TORONTO, Dec. 30, 2020 — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, is pleased to announce that the Company has acquired 49% of Canapar Corp. (“Canapar”) (the “Canapar Shares”). The Canapar Shares were acquired from Canopy Rivers Corporation (“Canopy Rivers”), a wholly owned subsidiary of Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF). Canapar, through its wholly owned subsidiary Canapar SrL (“Canapar Italy”), will be one of Europe’s largest vertically integrated Cannabis companies when fully operational. Canapar’s state of the art extraction plant is the largest in Europe and has been custom designed for the production of active compounds to be used in high-quality pharmaceutical, wellness and cosmetic products from its 1,000-hectare Italian-based organic hemp production and processing platform. The strategic investment is expected to immediately enhance RAMM and Canapar’s ability to capitalize on the rapidly expanding European and global cannabis markets, provide additional opportunities to expand RAMM’s distribution footprint for its portfolio of internationally registered and approved pharmaceutical and other cannabis-based products and further leverage Canapar’s significant investment in its extensive vertically integrated operation and industry expertise.

“Canapar is positioned to be a leader in the European Cannabis market and this strategic investment provides RAMM with a significant presence in Europe creating a prominent and differentiated global platform,” stated Jack Burnett, Chief Executive Officer of RAMM.

“We welcome RAMM as a strategic investor in Canapar and are very optimistic about the opportunities to cross-leverage our respective expertise, product portfolios and established presence in an expansive number of international markets”, stated Sergio Martines, Chief Executive Officer of Canapar.

A video overview of Canapar’s operations can be found he and additional information about Canapar and can be found on its website www.canapar.com .

About the European Cannabis Market

Europe represents one of the largest potential cannabis markets globally. The Europe cannabis market is currently valued at US$3.5 billion and expected to reach US$37 billion by 2027 with an anticipated CAGR of 29.6% from 2020 to 2027 (ResearchAndMarkets.com, 2020). European countries are experiencing a transformation in the regulations for marketing cannabis and related products, facilitating easier cultivation, processing, and trade of the cannabis-derived products across this region.

Terms of the Transaction

The Canapar Shares were acquired for C$7,000,000 pursuant to the terms of a share purchase agreement (the “Agreement”) and represent approximately 49% of the issued and outstanding shares of Canapar on a non-diluted basis. Canopy Rivers is also entitled to additional contingent consideration of C$2,000,000 payable in cash or issuable in common shares of RAMM, at the sole discretion of RAMM, on the achievement of certain production milestones at Canapar Italy’s production facility in Sicily. In accordance with the terms of the Agreement, RAMM was also assigned Canopy Rivers’ rights under an investor rights agreement which includes: (i) the right to designate one nominee to Canapar’s current three person board of directors (or two nominees if the size of the board increases to six persons or more); (ii) the right of Ramm to maintain its pro rata ownership percentage of Canapar in connection with future financings; and (iii) a call option providing RAMM with the right to purchase 100% of Canapar’s interest in its investees companies for the greater value of C$200,000,000 or eight times EBITDA.

About Canapar Corp.

Canapar with its wholly owned subsidiaries in Europe is an Italy-based manufacturer and processor of CBD oil and isolates, which are increasingly used as an input into new commercial products in the health and wellness industries. Canapar has secured more than 1,000 hectares of hemp through its outsource farming model and entered into an academic partnership with the University of Catania’s Department of Agriculture. Canapar is also advancing its CBD extraction and processing capabilities through its new facility and is expecting to transform 600 metric tons of hemp biomass annually into CBD isolates and derivative products for distribution in Europe following the commissioning of its extraction machinery. With demand for products that contain natural active ingredients derived from plant extracts increasing significantly, Canapar plans on developing CBD-infused cosmetics, skincare, and beauty products for the Italian cosmetics market, which is the fourth largest such market in Europe, as well as the global market, which provides strong demand for “Made in Italy” brands.

About RAMM Pharma Corp.

Led by renowned cannabis industry experts and backed by successful pioneers in the cannabis sector, RAMM is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. Founded in 1988 in Montevideo, Uruguay, the Company is a well established pharmaceutical and medical product business that has developed medically registered and approved plant-derived cannabinoid pharmaceutical products. The Company currently has multiple approved and registered products that have been authorized for sale in Uruguay and compassionate use in several Latin American countries, as well as a pipeline of new products in various stages of approval and development produced in the Company’s state of the art Good Manufacturing Practice (GMP) certified cannabis formulation facility. Further to its industry leading activities in the cannabis sector, the Company operates a successful pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been servicing the local market for 30 years.

RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA, Glediser SA and Ramm Pharma Holdings Corp.

Additional information about the Company is available at www.rammpharma.com .

For further information, please contact:

Jack Burnett
Chief Executive Officer
+598 2513 9958
info@rammpharma.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, ” forward looking statements “) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the Company’s strategies and objectives, and future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: the anticipated benefits of the acquisition of the Canapar Shares to the Company and its shareholders; the future growth potential of the Company on a post-acquisition basis ; commissioning of Canapar Italy’s extraction machines; efficacy of the Company’s product offerings; the expected timelines associated with the production, roll-out and availability of the Company’s products; the ability to meet increased demand for the Company’s products, changes in prices of required commodities; the impact of COVID-19 on the Company’s workforce, suppliers, partners, customers, and other essential resources and what effect those impacts, if they occur, would have on the Company’s business and operations; future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Wednesday, December 30th, 2020 Uncategorized Comments Off on $CNPOF RAMM Pharma Enters European Cannabis Market with Strategic Investment in Canapar Corp.

Knightscope, Inc. Adds Body Temperature Detection to Robot Security Products to Help Protect Facilities

  • The COVID-19 pandemic has sickened more than 78 million people worldwide, leading to the deaths of more than 1.7 million people
  • The pandemic has hammered businesses as society has attempted to lessen human contact in order to limit the spread of the virus responsible for the illnesses, especially as a growing number of employees of the stressed companies have needed sick leave
  • Autonomous Security Robot (“ASR”) developer Knightscope has enhanced its artificial intelligence-equipped sentries with elevated body temperature detection to help companies measure body temperatures of employees and visitors entering their facilities
  • The feature will help client companies protect their employees from virus transmission on their premises, potentially reducing liability concerns in the process

As vaccines to combat the novel coronavirus begin to rollout across the country, Americans are acknowledging that it may take weeks or a number of months before a significant reduction of the pandemic’s threat takes place (https://nnw.fm/ys2v9).

Autonomous security developer Knightscope has noted that one benefit of its robotic security teams patrolling select businesses and agencies across five time zones is that they are “immune and have been continuing to patrol across the country despite the pandemic” (https://nnw.fm/FsKGD).

Now, the robots are also helping to provide a sense of COVID confidence by enabling elevated body temperature detection from wherever the sentries are located.

“The Centers for Disease Control and Prevention indicates that a person with a temperature of 100.4 degrees or greater has a ‘fever,’ a symptom of COVID-19,” a recent Knightscope announcement states (https://nnw.fm/v7YAD). “In an effort to help combat the spread of COVID-19, Knightscope developed a way for its clients to measure body temperatures of employees and visitors entering a facility.”

The Pew Research Center reported in March that 24 percent of workers didn’t have access to any kind of paid sick leave prior to the pandemic, as noted in The Deseret News (https://nnw.fm/t4McS). Only 13 states currently require employers to offer paid sick leave. Fewer states passed temporary new measures in response to the coronavirus. But the need for sick workers to stay home if they’ve been infected means that businesses are not only under pressure as staffing levels become more critical, but also in dealing with the financial realities that their employees are wrestling with.

Knightscope’s new solution ultimately protects companies and their employees from the threat of virus transmission in the workplace as well as from the traditional external safety issues surrounding potential crime, fire and property damage matters.

“Our long-term ambition is to make the United States of America the safest country in the world,” the company’s website states.

For more information, visit the company’s website at www.Knightscope.com.

Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO.

DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Wednesday, December 30th, 2020 Uncategorized Comments Off on Knightscope, Inc. Adds Body Temperature Detection to Robot Security Products to Help Protect Facilities

$VTGN Penny Stocks Analysts Say Buy With 92%-284% Price Targets

Whether you’re looking for penny stocks to buy on Robinhood, ETrade, TD, Webull, Interactive Brokers, or other platforms, everyone has 1 goal. At least I would hope everyone has one goal, which is to make money. One of the interesting parts about that mix of brokers is some restrict access to certain stocks. Take penny stocks on Robinhood or Webull for instance. The vast majority are limited to just NASDAQ and NYSE stocks. When it comes to OTC penny stocks , these “mobile-first” platforms are very limited.

Keep in mind, however, that “listed” stocks (Nasdaq & NYSE) tend to get more attention from investment firms, in general. With that also comes interest from analysts. The Wall Street firms follow countless companies, weighing in on everything from earnings growth to pipeline products or treatments. What I will say is that analysts aren’t fail proof. But they do focus their energy on finding opportunities or risks that the investing community can use.

Penny Stocks To Buy According To Analysts

In my opinion, just because there’s a Buy or Sell rating doesn’t necessarily mean anyone should “definitely” buy or sell that stock. If anything it gives you a glimpse of sentiment. Can analyst actions impact stock prices? Yes and we’ve seen that in real-time over the last few weeks. But after the dust settles, it’s up to traders themselves to digest the information and fold it in with the rest of their analysis. Keeping this in mind, here are a few penny stocks with Buy ratings that also have hefty price targets. Will these find their way on your watch list before next year?

Penny Stocks To Buy [Lake Street Capital]: SeaChange International Inc.

SeaChange International Inc. has a Buy rating from Lake Street Capital. The firm also has placed a $2 price target on SeaChange shares. This puts their SEAC stock forecast 92% higher than Tuesday’s closing price.

It’s no secret by looking at the chart that SEAC has experienced a rough year. But it’s the last few months that I’m looking at right now. Since October 29th, shares have bounced from around $0.70 to highs this week of $1.10. Initially, the move was correlated with the general tech industry’s rebound following vaccine news. However, in December, things have become a bit more active both in the market and with the company.

The company reported strong earnings per share compared to estimates. SeaChange recorded a 10 cent loss per share in comparison to Wall Street’s 12 cent loss per share. Some things that helped with this had to do with strong demand from content owners for SeaChange’s new ‘Video Apps’ platform. This allows content owners to actually launch direct-to-consumer TV and video applications directly through Smart TVs and connected platforms.

What To Watch With SeaChange

Thanks to COVID, there are more people streaming entertainment. The company’s video apps platform allows independent content owners to distribute content while also leveraging a unique monetization strategy via advertising.

[Read More] Best Penny Stocks To Buy Right Now? 3 Under $3 For Your Watch List

Last week SeaChange discussed its SeaChange Framework. With the way people are accessing entertainment, digital platforms could be a focus in 2021.Scott Apgar, VP Advanced Advertising explained the idea further, “Many SeaChange Content Owner customers across the globe are using the Framework today to generate new advertising revenue streams through the automated sale of their ad inventory.”

penny stocks to buy SeaChange International Inc. SEAC stock chart

Penny Stocks To Buy [Maxim Group]: VistaGen Therapeutics

VistaGen Therapeutics Inc. is another one of the trending penny stocks to watch this month. Right now Maxim Group has a Buy rating on the stock along with a $5 price target. This puts Maxim’s VTGN stock forecast roughly 233% higher than Tuesday’s closing price. Similar to SeaChange, a lot of the momentum has come in December. In fact, since the start of the month, VTGN stock has climbed over 90%. What’s more is that since March, shares have bounced as much as 416%. The overall trend on the chart is clearly bullish. But as I said, some of the most aggressive moves have come this month.

Specifically, the company announced that it would raise $100 million in a public offering at $0.92. Now many times companies announce financing deals, the stocks tend to crumble. However, in this case, VistaGen’s stock was trading right around the same levels as the money was raised at. In response to the new cash, VTGN stock popped big. That’s likely in light. of the use of proceeds as well. VistaGen intends to use the money for research, development, manufacturing, and regulatory expenses associated with continuing the development of its pipeline treatments. This includes its PH94B, PH10, AV-101, and potential drug candidates to expand its CNS pipeline and for other working capital and general corporate purposes.

What To Watch With VistaGen

Aside from these latest highlights and fresh capital, there are other things to keep in mind. One of which is actually who invested in the latest funding round. Lead investors that participated in the offering include Acuta Capital, New Enterprise Associates, OrbiMed, and Venrock Healthcare Capital Partners. These are notable firms focused on advancing early-stage public companies. A few are specific to the biotech industry itself. Keep in mind that an extra $100 million doesn’t hurt especially when it comes to biotech pipelines.

“We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021. After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021,” said  Shawn Singh, Chief Executive Officer of VistaGen in the company’s fiscal 2021 Q2 business update.

penny stocks to buy VistaGen Therapeutics VTGN stock chart

Penny Stocks To Buy [Roth Capital]: Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc. has one of the highest price targets of the bunch. Roth Capital currently has a Buy rating on the stock as well as an $8 price target. That puts the firm’s HEPA stock forecast 284% higher than Tuesday’s closing price. The company has focused its efforts on developing treatments for non-alcoholic steatohepatitis or “NASH”.

Read More

The last few months have been volatile to say the least. Shares of HEPA stock were trading north of $4.70 during the summer. But several financing announcements did. the opposite of what VistaGen experienced. The penny stock eventually reached a low of $1.51 at the end of November.

December has been a much different month. Shares have actually recovered significantly by over 20% month-to-date. The excitement continued Tuesday morning as the company announced that an independent Data Safety Monitoring Board approved the continuation of the company’s Phase 2a ‘AMBITION’ clinical trial of its lead candidate, CRV431 in NASH. The final cohort is expected to be completed early next year.

What To Watch With Hepion

Heading into the end of the year, new information emerged late in the afternoon on Tuesday that should be noted. Hepion announced top-line data from the low dose cohort in its Phase 2a ‘AMBITION’ clinical trial of CRV431. The results of the low dose group showed that CRV431 was “generally safe and well-tolerated.” Furthermore, the pharmacokinetics “indicated that blood concentrations of CRV431 were similar to those observed in earlier Phase 1 studies in healthy volunteers, suggesting that the PK profile in moderate-to-severe NASH patients did not appear to be altered by disease.”

A second dosing cohort of 225 mg CRV431, which is the high dose is ongoing. Final results from both dosing cohorts are expected after the high dose group has completed active dosing, followed by a 14-day observation period.

penny stocks to buy Hepion Pharmaceuticals Inc. HEPA stock chart
Tuesday, December 29th, 2020 Uncategorized Comments Off on $VTGN Penny Stocks Analysts Say Buy With 92%-284% Price Targets

$WTER 420 with CNW – Growing Budget Deficit Could Force New York to Legalize Recreational Cannabis

In the last two years, the debate over the legalization of cannabis for adult use has dragged on in New York State. However, this may take a turn for the better next year as the state’s legislature goes back to Albany, despite the Democrats being divided on various aspects on the issue, which may make negotiations a tad bit difficult.

The main concern seems to be how the state will utilize the revenue generated from the recreational-use cannabis industry. According to forecasts from the state, the cannabis industry is expected to generate roughly $300 million each year once the industry stabilizes. The Marijuana Regulation and Taxation Act, which is supported by some Democrats in the legislature, would ensure that half of the revenue generated is set aside and invested in the communities that had drug laws by the state enforced at higher rates.

The bill is sponsored by the chair of the Finance Committee, state senator Liz Krueger, and Assembly Majority Leader Crystal Peoples-Stokes, D-Erie. Krueger stated that the individuals she has been working with are committed to this model and believe that revenue should be utilized for social justice purposes, because it would support communities of color that had been greatly affected by the drug wars.

Data from the state shows that, historically, in the city of New York, people of color are arrested more often for cannabis possession when compared to their white counterparts. According to the “Times Union,” this is also true for cities such as Albany. Clauses in the proposal stated that the state would develop a fund whose purpose would be to provide grants for local government entities and community-based NGOs that support those communities’ needs, including legal services and job placement.

While Democrats agree with the idea broadly, they disagree on a few minor details. Gov. Andrew Cuomo introduced a Cannabis Regulation and Taxation Act in 2019, which highlights similar issues such as the MRTA. However, it doesn’t set aside a specific amount of funds to be allocated to communities affected by the war on drugs. This has become a bone of contention for the legislature.

Apart from this, other issues include the different tax rates set for consumers in the marijuana market, with the legislature bill setting the rate at 18% and Cuomo’s legislation creating a 20% tax for consumers.

In addition to this, legislators can’t agree on whether to allow consumers to cultivate their own cannabis plants at home and, if so, how this would be regulated. Cuomo’s plan does not allow this option while Krueger’s does.

Road safety is also another issue, seeing as there’s no easy way to test whether an individual is driving under the influence of cannabis.

Away from the legalization debates in New York, Arizona-based The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is carving out a name for itself as the maker of the best pH-balanced alkaline drinking water. In additions, its CBD-infused products are very popular.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Tuesday, December 29th, 2020 Uncategorized Comments Off on $WTER 420 with CNW – Growing Budget Deficit Could Force New York to Legalize Recreational Cannabis

$SGTM Poised to Assist in Recovery Efforts as Snow Storms Ravage North Eastern United States

December 29, 2020

Sustainable Green Team Ltd (SGTM) Poised to Assist in Recovery Efforts as Snow Storms Ravage North Eastern United States

  • One of recent history’s largest snowstorms struck United States’ Eastern seaboard in mid-December
  • Over 60 million Americans were placed under winter storm advisories, with the Governors of New York and Pennsylvania declaring state of emergency
  • 2020 has been characterized by its extraordinary storm season, which has already seen six major hurricanes and 30 tropical storms cause estimated $38 billion in overall damage
  • Sustainable Green Team specializes in providing environmentally beneficial solutions for tree, storm waste disposal
  • Company witnessing surge in demand for tree recovery and debris collection services as result of ongoing storm season

The week of December 14, 2020 brought with it the biggest winter storm to hit the United States’ mid-Atlantic seaboard in years. Heavy snows moved into New York City with the National Weather Service forecasting that some areas in northeastern United States would receive as much as 20 inches of snow as a result of the moisture-laden system, placing it amongst the heaviest December snowstorms on record (https://ibn.fm/fLAjw). However, the Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has been preparing for just such an eventuality in a year which has already been marked by a series of extraordinary weather events.

The Sustainable Green Team’s wholly owned subsidiary, National Storm Recovery LLC, is composed of a team boasting expertise in dangerous tree removal, debris hauling and debris management. The company’s management team assesses storms by deploying its mobile command center to designated sites and then strategizing with its national partners, which include government agencies, prime contractors and subcontractors.

While damage assessments from the snowstorm are yet to be disclosed, they are likely to be significant in nature. Over 60 million Americans have been placed under winter storm advisories, watches and warnings in a vast swathe of area ranging from northern Georgia to New England, with the governors of New York and Pennsylvania responding to the snowstorms by declaring a state of emergency – as a cold weather front, wind gusts topping 50 mph and high levels of snowfall ravage the eastern seaboard (https://ibn.fm/Psxa3). Meanwhile, state utilities have warned residents to be prepared for potential power outages, in the event of downed power lines or other related mishaps (https://ibn.fm/EUHqN).

“Confidence is high that this winter storm will result in significant impacts, including travel disruptions and power outages across much of the mid-Atlantic and southern New England,” the Weather Prediction Center noted (https://ibn.fm/ob3Or).

The 2020 Atlantic hurricane season was one that was destined for the record books before it even started. Meteorologists began calling for an above-average storm season as early as December 2019 (https://ibn.fm/OXmvY), with predictions of 15-20 named storms and four major hurricanes. However, in remarkable contrast to initial forecasts, the Atlantic hurricane season has thus far comprised of upwards 30 tropical storms, 13 hurricanes and six major hurricanes with initial assessments estimating the cumulative economic impact of the storms at over $38 billion (https://ibn.fm/3WIZb).

Nonetheless, the active storm season has led to a commensurate increase in the demand for tree recovery/collection services, which in turn has translated into greater sales for the Sustainable Green Team’s services.

“Storm recovery is a multibillion-dollar business, and we are prepared to help in any cleanup process,” stated SGTM CEO and Director Tony Raynor.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/0TBkF.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, December 29th, 2020 Uncategorized Comments Off on $SGTM Poised to Assist in Recovery Efforts as Snow Storms Ravage North Eastern United States

$POAI Predictive Oncology Announces Cancellation of Special Meeting in December 2020

Reincorporation Proposal Received Overwhelming Support Among Shares Voted

NEW YORK, Dec. 29, 2020 — Predictive Oncology (NASDAQ: POAI) (the “Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Board of Directors has decided to cancel its Special Meeting of Stockholders that was originally scheduled for December 1, 2020. On that date, the meeting was adjourned to December 30, 2020 because a quorum was not reached. As of December 30, 2020, approximately 47% of the outstanding shares as of the record date have been voted, and therefore a quorum has still not been reached. The Board of Directors has determined that it is not practical to incur the expense of adjourning the meeting further to continue to solicit proxies, because approval of the reincorporation proposal would require the affirmative vote of a majority of the Company’s outstanding shares (not simply a majority of the shares voted).

The Board notes that, of the shares that were voted at the Special Meeting, nearly 88% of the shares were voted FOR the reincorporation from Delaware to Nevada. In the future, the Board intends to continue to seek stockholder approval for reincorporation, due in part to the oppressive franchise taxes charged by Delaware.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Hayden IR
James Carbonara
(646)-755-7412

Tuesday, December 29th, 2020 Uncategorized Comments Off on $POAI Predictive Oncology Announces Cancellation of Special Meeting in December 2020

Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc.

Cybin Inc. ( NEO:CYBN ) (“ Cybin ”), a life sciences company focused on psychedelic pharmaceutical therapies, announces the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended October 31, 2020. A copy of the unaudited consolidated financial statements prepared in accordance with International Financial Reporting Standards and the corresponding management’s discussion and analysis for the three months ended October 31, 2020 can be found under Cybin’s profile at www.sedar.com .

About Cybin

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Cautionary Notes and Forward-Looking Statements

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin’s expectations, estimates and projections regarding future events. These statements are not guaranteeing future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this press release are made as of the date of this press release. The Company does not undertake an obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date.

Investors:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

Media Liaisons :
Jackie Poriadjian
Chief Marketing Officer, CYBIN
Jackie@cybin.com

Annie Graf
KCSA Strategic Communications
agraf@kcsa.com

Tuesday, December 29th, 2020 Uncategorized Comments Off on Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc.

$CNSP Hour of Truth Approaching in CNS Pharmaceuticals Testing of Drug Candidate Against Deadly Brain Cancer

  • A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next year
  • The drug, Berubicin, is being developed by CNS Pharmaceuticals after initial testing nearly 15 years ago resulted in improvements among some subjects, including one who has survived cancer-free since that time
  • The company, in collaboration with Polish sub-licensee partner WPD Pharmaceuticals, plans a multinational staged series of trials that will attempt to keep time and costs to outcome at a minimum
  • As part of the effort, CNS and WPD plan to conduct the first-ever pediatric Phase 1 trial of Berubicin in children with no other recourse

Brain cancers that are relentless and effectively incurable have caught the attention of drug maker CNS Pharmaceuticals (NASDAQ: CNSP), which is working to complete testing of its lead candidate in hopes of finding a cure against those central nervous system disorders.

The drug, Berubicin, is an anthracycline with the novel distinction of being able to cross the blood-brain barrier to combat tumors — something all other anthracyclines are unable to do. Nearly 15 years ago, Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals. The limited study resulted not only in a finding of safe usage, but in two patients reductions of greater than 25 percent in the size of their tumors (one achieved an 80% reduction in the tumor) while another patient became cancer-free (known as a durable complete response) and has remained cancer-free to the present, as noted in a recent company webinar (https://ibn.fm/WnXTx).

CNS obtained rights to Berubicin and its related clinical data. The company was awarded Orphan Drug Designation (“ODD“) for Berubicin in treating malignant glioma cancers (an indication much broader than the current investigational target of glioblastoma multiforme) and announced Nov. 17 that it had filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”), which had been accepted for review (https://ibn.fm/T6idd). Thirty days later the Company announced that its IND for Berubicin for the treatment of Glioblastoma Multiforme (“GBM”) was approved and in effect as filed with the US Food and Drug Administration (“FDA”).

CNS continues to methodically develop its plan of attack with Berubicin, planning to launch a Phase 2 trial during the first quarter of 2021, which will involve randomized and controlled comparative administration of Berubicin and the chemotherapy drug lomustine to 243 patients. Lomustine is widely considered to be the second-line standard-of-care therapy despite not being formally approved as such.

The trial will take place at about 60 study centers in North America, Europe and the Asia-Pacific region, searching for proof that Berubicin patients may benefit from reduced tumor size or even just from arrested development of the tumor’s growth. And, ultimately, the overall survival of the patients, of course.

Glioblastoma patients have been found to have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis. With surgical intervention, the cancer tends to recur and adapt to pharmaceutical interventions. The Phase 1 patient’s survival without cancer recurrence during the past 14 years is seen as significant cause for optimism.

Concurrent with the multinational Berubicin trial, CNS Pharmaceuticals is partnering with Europe’s WPD Pharmaceuticals to launch a first-ever Phase 1 Berubicin pediatric safety trial in Poland during Q1 of 2021 for children who have the GBM tumor and have run out of other medical options. WPD will also conduct a Phase 2 trial on the adult use of Berubicin. Under the licensing agreement, WPD will pay a minimum of $2 million on the development of Berubicin and pay CNS a royalty fee on sales.

WPD received a $6 million development grant in January from the European Union to complete the two trials, which significantly increases CNS’s ability to complete the Berubicin trials without the degree of spending and equity dilution that might have occurred otherwise. In an effort to further control those outlays of capital, CNS CEO John Climaco stated during the webinar that the company will complete the trials in stages over the next two to two-and-a-half years, funding each successive stage as results from achieved milestones show the efficacy of continuing to proceed forward.

The trials are expected to cost $30 million to $35 million by the time they are completed. In the meantime, the company also hopes positive results from the trials will convince the FDA to grant Berubicin an expedited pathway to approval, which would reduce the time and cost of the trials to an even greater degree. The company recently announced the sale of $10 million of stock in a public offering and has also secured up to $15 million in potential equity financing via an equity line facility with Lincoln Park Capital.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Tuesday, December 29th, 2020 Uncategorized Comments Off on $CNSP Hour of Truth Approaching in CNS Pharmaceuticals Testing of Drug Candidate Against Deadly Brain Cancer

$RACMF Shareholder Letter Outlines Highlights of Most Successful Year in History

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) CEO Rob Anson has released a recent shareholder letter calling 2020 an extraordinary year and outlining the company’s significant accomplishments. A provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick-and-mortar space, Loop Insights has seen a year full of firsts and noteworthy partnerships, products and financing. The letter provided a review of the highlights for the company, including its selection to join Amazon Web Services Partner Network and the interactive webinar RACMF hosted with Amazon Web Services to showcase Loop’s venue-tracing capabilities. Loop Insights also had two products accepted into the Telus IoT Marketplace: its proprietary contact-tracing product and its Insights service, which consists of RACMF’s IoT Fobi device, Loop Cloud API, and AI Insights Portal. In addition, Loop announced retail partnerships with both Vend and Shopify and played a key role in the first-ever venue bubbles in a live environment. Most recently, the company announced that it had joined KABN Systems NA Holdings Corp. (CSE: KABN), Liquid Avatar, Lumedic, the Campus Agency and TripXpertz to form a consortium to manage verifiable identity credentials for COVID-19 vaccinations; Loop also announced the January 2021 launch of its Digital Connect Health Platform, a fully integrated digital healthcare solution designed for both government and private sector. “As shareholders can see from this year in review, Loop had an incredible year in 2020, and more importantly, is positioned with the right partners, products, pipeline, and financial resources to make the same quantum leap in 2021,” Anson stated in the press release. “Our success is reflective of our hard work and the exceptional quality of our people. Our team has grown and we’ve welcomed many passionate members who continue to drive innovation here at Loop. Despite the challenges created by the COVID-19 pandemic, the Loop team has overcome all obstacles and continues to work to drive the growth of the company, whether working remotely or together in our Vancouver office. We can’t wait to get back to work and deliver more big wins for our shareholders.”

To view the full press release, visit http://ibn.fm/fQlT1

About Loop Insights Inc.

Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. RACMF’s ability to integrate seamlessly into existing infrastructure and customize campaigns according to each vertical creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality and retail industries in Canada, the United States, the UK, Latin America, Australia, Japan and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information about the company, please visit www.LoopInsights.ai.

NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Tuesday, December 29th, 2020 Uncategorized Comments Off on $RACMF Shareholder Letter Outlines Highlights of Most Successful Year in History

$VTGN Featured in Equity Research Report

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on its pharmaceutical pipeline coupled with financing and a rising mental health pace. The report reads, “On 12/18, VistaGen announced pricing of an equity financing, raising gross proceeds of $100M (~$93M net) and bringing the company’s cash balance to ~$103M. Importantly, the financing included participation of some leading institutional health care investors, which in our view is further validation of VistaGen’s mental health-focused pipeline (NMDA modulation, nasal-active pherines (PH94B, PH10)) and management’s ability to execute. We are also now factoring in PH10 into our model and the increased cash balance, which raises our PT to $5, from $3.”

To view the full report, visit http://ibn.fm/zbWAX

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on $VTGN Featured in Equity Research Report

$SRAX Hosts LD Micro’s 13th Annual Main Event on Sequire Platform; Investment World Eyes Micro-Caps

December 28, 2020

SRAX Inc. (SRAX) Hosts LD Micro’s 13th Annual Main Event on Sequire Platform; Investment World Eyes Micro-Caps

  • Analysts recommending small cap stocks for both growth and value amid large cap overvaluations, decreased momentum
  • SRAX subsidiary LD Micro hosted 13th Annual Main Event featuring nearly 250 prominent and emerging micro-cap companies
  • Two-day virtual conference was hosted on SRAX’s Sequire platform from December 14-15, 2020
  • 2 million+ active small cap investors invited from LD Micro’s loyal investor base

Large cap technology growth stocks like Amazon and Tesla have seen a massive wave of investor momentum as a result of COVID-19. The resulting overvaluations and decreased momentum in recent weeks, however, are prompting some analysts to recommend a shift back to small cap value investments (https://ibn.fm/FSEQm). LD Micro, a prominent resource to the microcap world, recently covered nearly 250 established and emerging micro-cap companies at its 13th Annual Main Event on December 14-15, 2020. The event was hosted by SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, on Sequire – its virtual events and investor analytics SaaS platform.

Despite the impressive gains seen on the Nasdaq this year, the index has returned 10.5% so far in December while the Russell 2000 and Russell Micro-Cap indices have returned 25.8% and 27.6%, respectively. This wide difference in returns and valuations is prompting investors to focus their attention on small cap value stocks – a trend that is expected to continue well into 2021 (https://ibn.fm/JN2F6).

LD Micro, now a wholly owned SRAX subsidiary, has been a respected source of quality investor information to the small cap investment community for nearly 15 years. Almost 2 million active small cap investors from its loyal base have been invited to the two-day virtual conference that will feature an all-new format that promises to deliver a unique experience for all participants. Along with nearly 250 companies across the micro-cap world, the special event also featured special keynotes by guests such as Shaquille O’Neal & Brock Pierce.

The conference marks the debut of Sequire’s virtual events platform, a new addition to SRAX’s current suite of solutions for public companies that help them attract and engage new investors and existing shareholders in a single place.

“We are excited to bring together one of the largest communities of micro-cap investors to hear from amazing companies,” said SRAX Founder and CEO Christopher Miglino. “The LD Micro conference has a long history of driving awareness for companies and is just one of the many benefits that the Sequire platform brings to the table when helping public companies.”

The advent of new technology, coupled with increasing market complexity, has created a novel demand for sophisticated investor relations applications. SRAX provides those solutions through Sequire, its data-based SaaS software that addresses this demand through a suite of tools that helps public companies unlock the power of data to reveal investor behaviors and trends.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on $SRAX Hosts LD Micro’s 13th Annual Main Event on Sequire Platform; Investment World Eyes Micro-Caps

$NETE Are Power Grids in Cities Ready for Widespread EV Uptake?

As part of a global push to reduce carbon emissions and improve air quality, several governments, cities and states have issued bans against the sale of internal combustion engine vehicles in favor of electric vehicles (“EVs”). Europe undoubtedly leads the race towards electrifying its roads thanks to its ambitious ICE vehicle bans, with at least seven European countries pledging to ban the sale of new ICE vehicles over the next 30 years.

But as EV adoption increases over time, will power grids in cities be able to handle the increased demand for electricity? The European Union saw a 122% increase in the electric and PHEV sales over the first three quarters of 2020, representing about 8% of total new vehicle sales. In Sweden, electric automobiles took up a 28% share of auto sales for the first nine months of this year translating to 56,559 PHEVs or fully electric vehicles bought.

Despite the uptick in EV adoption, Stockholm has less than 4,000 charging stations publicly accessible and will require 25,000 stations by 2030 to keep up with the demand for power, says Kristofer Fröjd, the head of business development at Stockholm’s power distributor Ellevio. Even if the city is able to install the required chargers in time, the country’s power grid is often stretched to capacity, especially during winter when demand peaks. In the future, EV drivers may have to deal with slower charging speeds as power providers balance the demand for domestic heat with transport needs.

According to Per Eckemark, Svenska Kraftnät’s grid executive manager, electric vehicles will consume almost 10% of Sweden’s electric output by 2045, up from 0.4%. Svenska Kraftnät, which is the country’s national transmission grid operator, plans to rebuild one-third or roughly 3,107 miles of the country’s grid at a cost of $17.9 billion by 2030. However, officials assert that the additional power output will not be enough to forestall the country’s grid from being severely strained come 2022.

The situation is almost identical in most territories that are phasing ICE vehicles out in favor of EVs. Britain will need 2.8 million chargers at a cost of $22.07 billion by 2035 to meet power demands. In Canada, the province of British Columbia is projected to be home to approximately 350,000 EVs by 2030, requiring an additional 1,050 gigawatts hours of electricity per year.

Meanwhile, the EV industry is surging forward as it attempts to address the rapidly changing needs of car buyers. Nowhere else is this revolution evident than in the recent announcement by Net Element (NASDAQ: NETE), a global payments solutions provider, revealing that it was in the process of merging with a EV manufacturer based in Southern California.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on $NETE Are Power Grids in Cities Ready for Widespread EV Uptake?

$NETE Positioned Amid Surging Demand in EV Space

Net Element (NASDAQ: NETE), a financial technology company in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc., is poised as the EV sector has seen a sharp uptick in consumer demand and investor interest. Rising demand is driven by a combination of improved sector fundamentals coupled with positive industry news. A recent article discussing the company reads, “A potential combined Net Element-Mullen Technologies entity plans to leverage upon the surge in consumer demand within the electric vehicle space through the launch of its initial vehicle model – the Dragonfly K50—in the second quarter of 2021. The car model, developed in conjunction with China’s Qiantu Motors, will mark the company’s initial foray into the North American electric vehicle market, a venture which the company will further look to reinforce through the launch of its self-manufactured EV SUV, the Mullen MX-5, by the second quarter of 2022.”

To view the full article, visit https://ibn.fm/93wvE

About Net Element Inc.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). The contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visitwww.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on $NETE Positioned Amid Surging Demand in EV Space

$GNPX Secures $12M in Registered Direct Offering

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has announced the closing of its registered direct offering of 3,116,884 shares of its common stock with a single health care-dedicated institutional investor. Genprex secured gross proceeds of $12 million, before deducting commissions and estimated expenses, with the offering priced at-the-market under Nasdaq rules at a price of $3.85 per share. “We believe that the closing of this transaction with a single, health care-dedicated institutional investor is further evidence that the potential of our gene therapies for cancer and diabetes is gaining recognition within the community of sophisticated health care investors,” said Rodney Varner, president and CEO of Genprex. “The proceeds will provide additional resources to conduct our Acclaim-1 and Acclaim-2 clinical trials, combining our gene therapy, REQORSA, with Tagrisso (by Astra Zeneca) and Keytruda (by Merck & Co.), respectively, for the treatment of non-small cell lung cancer, as well as continue the pursuit of our pre-clinical programs in cancer and diabetes, and to potentially acquire additional technologies for our pipeline.”

To view the full press release, visit http://ibn.fm/1gQH0

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site atwww.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on $GNPX Secures $12M in Registered Direct Offering

Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression

Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in symptoms in adults with major depression (https://ibn.fm/ZpmzM). “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” stated Alan Davis, PhD., adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. A recent article discussing this reads, “These results confirm that Cybin, committed to becoming one of the first life science companies to develop a fully approved psilocybin product targeting depression, is on the right track. CYBN is intent on providing solutions to the more than 17 million people in the United States and 300 million people worldwide who suffer from depression. The company has been focusing its efforts on psychedelic drug development and unique delivery mechanisms and protocols that target psychiatric and neurological conditions.”

To view the full article, visit https://ibn.fm/QU6P6

About Cybin Inc.

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression

$CNSP Featured in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ Investigational New Drug (“IND”) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (“GBM”). The IND is now approved and in effect as filed with the U.S. Food and Drug Administration (“FDA”). “Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” said John Climaco, CEO of CNS Pharmaceuticals. “The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase 2 trial in the U.S., and 2 trials planned by our sublicensee WPD in Poland. We are entering an area with significant unmet medical need since the current treatment paradigm for GBM remains bleak, as this aggressive and currently incurable form of brain cancer continues to claim high mortality rates. We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial.”

To view the full press release, visit http://ibn.fm/kSVfH

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, December 28th, 2020 Uncategorized Comments Off on $CNSP Featured in Syndicated Broadcast